For example, applied clinical risk scores (such as WATCH‐DM) and biomarkers like NT‐proBNP and hs‐cTn in a cohort of over 6000 diabetic patients demonstrate that a two‐step screening strategy could reduce the number needed to screen and lower costs. This evidence concerns the gene NPPB and diabetes mellitus.